4DMT Announces Presentations at ARVO 2024 Annual Meeting [Yahoo! Finance]
4D Molecular Therapeutics, Inc. (FDMT)
Company Research
Source: Yahoo! Finance
4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a poster EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Seattle, Washington on May 5-9, 2024. 2024 ARVO Annual Meeting Presentation Details: Title: Interim results from the PRISM randomized Phase 2 Dose Expansion trial evaluating 4D-150 in high anti-VEGF need individuals with neovascular (wet) age-related macular degeneration Poster Session: AMD-3 (clinical research), 416 (Poster A0075) Date/Time: Wednesday, May 8, 2024 (10:30 a.m. PT) Presenter: Arshad M. Khanani, M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associate
Show less
Read more
Impact Snapshot
Event Time:
FDMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FDMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FDMT alerts
High impacting 4D Molecular Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FDMT
News
- 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.MarketBeat
- We're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To Grow [Yahoo! Finance]Yahoo! Finance
- 4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023) [Yahoo! Finance]Yahoo! Finance
- 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights [Yahoo! Finance]Yahoo! Finance
- 4DMT Reports First Quarter 2024 Financial Results and Operational HighlightsGlobeNewswire
FDMT
Earnings
- 5/9/24 - Beat
FDMT
Sec Filings
- 5/9/24 - Form 8-K
- 5/9/24 - Form 10-Q
- 4/18/24 - Form 4
- FDMT's page on the SEC website